



ASX Announcement

2 June 2020

Change of Director's Interest – Appendix 3Y

Invex Therapeutics Ltd (Invex, ASX: IXC, or the Company) provide the following update in relation to Dr Jason Loveridge's relevant interest in securities held in the Company.

Due to the ongoing liquidation of Warambi Sarl a company of which Dr Jason Loveridge is a shareholder and beneficiary, the beneficial interests of the shareholding in Invex have been distributed to the respective beneficiaries. As a result, Warambi Sarl's shareholding in Invex have been transferred to Warambi Ltd (a company which Dr Jason Loveridge is a shareholder and beneficiary), Dr Jason Loveridge and the balance of the shareholding has been transferred to other beneficiaries of which Dr Jason Loveridge does not have a 'notifiable' interest. The escrowed portion of these shares remain escrowed until 3 July 2021.

Dr Jason Loveridge will participate in Tranche 2 of the Placement as announced on the 22 May 2020 and for the purposes of Listing Rule 10.11, approval will be sought at the General Meeting of Shareholders, for the Company to issue up to 38,462 Shares to Dr Jason Loveridge (or his nominee).

Further details with respect to Dr Jason Loveridge's interest in securities are provided in the attached Appendix 3Y.

This release dated 2nd June has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics and lodged by Narelle Warren, Company Secretary.

ENDS

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| |
|--|
| Name of entity Invex Therapeutics Ltd |
| ABN 29 632 145 334 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|--------------------|
| Name of Director | Dr Jason Loveridge |
| Date of last notice | 22 November 2019 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|--|
| Direct or indirect interest | Indirect |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Shareholder and Beneficiary of Warambi Sarl and Warambi Ltd |
| Date of change | 28 May 2019 |
| No. of securities held prior to change | Dr Jason Loveridge – 1,566,000 ordinary shares Warambi Sarl – 3,540,000 ordinary shares. Dr Jason Loveridge – 800,000 unlisted options |
| Class | Ordinary shares |
| Number acquired | Warambi Ltd 1,145,000 ordinary shares transferred from Warambi Sarl Dr Jason Loveridge 625,000 ordinary shares transferred from Warambi Sarl. |
| Number disposed | Warambi Sarl 3,540,000 ordinary shares transferred to beneficiaries on liquidation. |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | \$277,927 net consideration relating to off market transfers. |

+ See chapter 19 for defined terms.

| | |
|---|--|
| No. of securities held after change | 1,145,000 ordinary shares – Warambi Ltd 2,191,000 ordinary shares – Dr Jason Loveridge 800,000 unlisted options exercisable at \$0.60 on or before 22 November 2023 subject to certain vesting conditions – Dr Jason Loveridge |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Liquidation of Warambi Sarl Off market transfer of 1,770,000 ordinary shares to other beneficiaries of Warambi Sarl 1,145,000 ordinary shares to Warambi Ltd 625,000 ordinary shares to Dr Jason Loveridge |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|--|
| Detail of contract | |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – ⁺Closed period

| | |
|---|--|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

⁺ See chapter 19 for defined terms.